Paediatric Strategy Forums

In collaboration with the European Medicines Agency, ACCELERATE invites you to submit your Expression of Interest (EOI) to the 16th Paediatric Strategy Forum for the Development of Medicinal Products: Targeting B7H3 in children and adolescent malignancies.

29 & 30 October 2026

Campus des Cordeliers

Paris, France and Online

The 16th Multi-Stakeholder Paediatric Strategy Forum (PSF) for the Development of Medicinal Products is organised by ACCELERATE in collaboration with the European Medicines Agency (EMA) and with the participation of the U.S. Food and Drug Administration (FDA) will focus on medicinal products targeting B7H3.

 

Background: Paediatric Strategy Forums have been created to evaluate the current state of the science, facilitate dialogue, and provide an opportunity for constructive discussions between relevant stakeholders (patient advocates, clinicians, academics, biotechnology/pharmaceutical companies, and regulators) on specific topics in an open forum to assure development of medicines in the best interests of children and adolescents with cancer. The goal of these meetings is to share information, to facilitate prioritisation for the development of innovative medicines and ultimately their introduction into the standard-of-care of children with malignancies.

 

Scientific rationale:

Cluster of Differentiation 276 (CD276) or B7 Homolog 3 (B7-H3) is a human protein encoded by the CD276 gene. In malignant tissues, B7-H3 is an immune checkpoint molecule that inhibits tumor antigen-specific immune responses. It is expressed in many cancers, including several paediatric malignancies. There are numerous assets targeting B7H3 in preclinical and clinical development: naked antibodies, bispecific antibodies, antibody drug conjugates, CART cells, radiopharmaceuticals. These developments are conducted both by industry and academia.

 

Objectives: The Paediatric Strategy Forum aims to i) clearly ascertain the role of targeting B7H3 in paediatric cancer; ii) identify which of the many types of inhibitors are of highest value for children and adolescents; iii) identify the relevant malignancies with unmet medical needs, and iv) facilitate prioritisation of assets for the treatment of paediatric malignancies.

 

The Forum will discuss all types of B7H3 inhibitors (antibodies, radiolabelled antibodies, bispecific antibodies, antibody drug conjugates, cellular therapies) in all relevant paediatric and adolescent malignancies.

 

The goal is to formulate a consensus between all stakeholders on how best to take forward the development of this class of medicinal products.

Format: This forum will be held in-person, and all participants are strongly encouraged to attend in person. For attendees unable to travel or if travel restrictions prevent attendance at an in-person event, a virtual option will be available. 

 

Forum Output: Publication of a summary and manuscript from all participants addressing the challenges and documenting the conclusions of the meeting. Potentially further specific meetings relating to areas which require more in-depth discussion will be arranged.

Participation: possible only by invitation or by submitting an Expression of Interest (see below) by 5 June 2026.

 

Submit your Expression of Interest: The call for expressions of interest is now open – click on "Submit Expression of Interest" below to apply. Invitations will be sent out by early July 2026.